Elizabeth (Liz) Moench

In today's edition of the NPC Healthbiz Weekly newsletter from the National Pharmaceutical Congress: The #pharmaceutical industry faces a critical challenge: delivering medicines to the world's poorest populations. While successful in many areas, our current approaches fall short in addressing global health disparities. Some key considerations: 1. Rethink global access strategies 2. Invest in infrastructure in developing regions 3. Apply lessons from Covid-19 vaccine distribution So, here's a question: Looking at the challenges of 2025, isn't it time the industry innovated its approach to ensure life-saving therapies reach those who need them most, regardless of geography or economic status? NPC Healthbiz Weekly is created by Chronicle Companies. Let us know what you think. https://lnkd.in/g-CQaGNb #lifesciences #leadership #pharmainnovation #globalhealth

4

National Plan for Affordable Healthcare: A Basic Human Right This note outlines a comprehensive plan for affordable healthcare, drawing on extensive data and insights from Elixir Healthcare USA. Our vision is rooted in the belief that healthcare is a fundamental human right, and that by prioritizing the health of our citizens, we can foster a stronger, more productive society. The strategies presented here are informed by current research, best practices, and the pressing needs of communities across the nation. We aim to create a sustainable and equitable healthcare system that ensures everyone has access to essential services, regardless of their socio-economic background. Together, we can build a healthier future for all. https://lnkd.in/ex5AZnEP

1

The potential benefits of GLP-1s continue to grow. The phase 2b ELAD study showed adults with early-stage Alzheimer's disease (AD) taking the GLP-1 receptor agonist liraglutide exhibited slower decline in memory and thinking and experienced less brain atrophy over 12 months vs placebo. Over 55 million people have dementia worldwide, costing economies globally 1.3 trillion US dollars Obviously, more research and bigger trials are needed but the unmet need is high. https://lnkd.in/eEiBTx2N #biotech #dementia #healthcare

5

A new survey shows that almost half of Americans can't afford healthcare. https://lnkd.in/gd_MC6TK Similarly, a new report from the UK finds access to oral healthcare is diminishing because of the cost of living crisis. https://lnkd.in/gDVPrmjh Things must change in how we deliver care if these deep-seated problems are to be overcome. How so? 1. we need to deal with the primary cause of poor oral health -- dysbiosis. 2. we need to take oral healthcare to the community so that the 1 in 3 adults who can't or won't go to the dentist, are served. 3. we need to make oral healthcare painless and quick so that the many who can't sit in a dental chair, can receive treatment. We hear frequently that poor oral health is entirely preventable. Why then is it not? #Prevora responds to the 3 needs described above. It is not surprising that Prevora is rated as " very important" by Canadian seniors. It is what they've been looking for.

5

Good read that highlights key findings from an analysis of expanding coverage of obesity medications in Medicare. Key points: - the annual costs would increase from $1.6B in 2026 to $7.1B in 2034 - per patient annual cost would be $5,600 in 2026 and $4,300 in 2034, highlighting price pressure - potential health savings seem to be limited in this analysis https://lnkd.in/gMtCUkvx #weightloss #Medicare #insights

4

10 Precision Oncology Advances of 2024: Transforming Patient Outcomes Through Clinical Trials As 2024 concludes, precision oncology clinical trials have delivered groundbreaking advancements redefining cancer treatment. Below are 10 breakthroughs, their benefits, and next steps in clinical application: 1. Tumor-Agnostic Therapies Expansion Benefit: Broader access to therapies targeting mutations like NTRK and RET, regardless of cancer origin, has improved survival rates for rare cancers. Next Steps: Increase trial enrollment to confirm efficacy across additional subtypes. 2. AI-Powered Biomarker Identification Benefit: Faster and more accurate patient-matching to trials ensures personalized treatments. Next Steps: Expand AI datasets to include underrepresented populations. 3. Circulating Tumor DNA (ctDNA) for Early Detection Benefit: Non-invasive liquid biopsies enable earlier detection of recurrence in breast and lung cancers. Next Steps: Validate ctDNA tests across larger, diverse populations. 4. CAR-T Therapy for Solid Tumors Benefit: First successful application of CAR-T cells in solid tumors like pancreatic cancer shows promise for hard-to-treat cases. Next Steps: Optimize delivery systems to enhance efficacy and reduce toxicity. 5. Neoantigen Vaccines Benefit: Personalized cancer vaccines show durable responses in melanoma patients. Next Steps: Extend trials to lung and colorectal cancers. 6. Organoid-Based Drug Screening Benefit: Patient-derived tumor organoids enable faster, more accurate drug selection tailored to cancers. Next Steps: Scale this approach for use in standard care. 7. Radiopharmaceuticals Benefit: Targeted radioligand therapy achieves remarkable outcomes in metastatic prostate cancer. Next Steps: Explore combination therapies to maximize response rates. 8. Expanded KRAS Inhibitors Benefit: Advances in KRAS G12D inhibitors extend precision treatments to pancreatic and colorectal cancers. Next Steps: Evaluate resistance mechanisms to refine regimens. 9. Targeting the Tumor Microenvironment Benefit: Therapies disrupting immune evasion pathways revitalize immune responses in resistant cancers. Next Steps: Launch larger-scale trials for late-stage cancers. 10. Dual-Target Antibody Therapies Benefit: Bispecific antibodies targeting HER2 and HER3 enhance outcomes in HER2-positive breast and gastric cancers. Next Steps: Investigate combinatorial approaches with immunotherapies. 🏆These milestones demonstrate precision oncology’s immense potential to deliver targeted, effective, patient-centered care. 🤝Greater collaboration, diverse trial enrollment, and equitable access are key to ensuring these advances benefit all patients. 🙋‍♀️Which advancement excites you most? 👇Share your thoughts below!👇 ⭐️If you’re planning or operating oncology or rare disease contact me to explore solutions tailored to your specific needs. Let’s ensure your trials achieve maximum success!

3

2 Comments

Struggling to Translate Brand Strategy into Actionable Medical Plans? You're not alone. Many Medical Affairs Managers, Advisors, MSLs face the challenge of bridging the gap between a compelling brand strategy and a clear, tactical Medical plan. Traditional approaches often leave you with unanswered questions: ⏹ How do I identify and address stakeholder needs effectively? ⏹ What concrete actions will drive progress towards my objectives? ⏹ Can I define and track metrics that showcase the true impact of my brand strategy? Introducing the Wolf Medical Strategy Framework! A Structured Approach for Success This framework is your roadmap to translating brand vision into a winning Medical plan. It goes beyond broad strokes, providing a structured approach that: ⏹ Uncovers critical stakeholder gaps: We help you to delve deep to understand the unique needs and motivations of all relevant stakeholders, ensuring your plan resonates with everyone who matters. 🔎 ⏹ Develops targeted tactics: No more generic "spray and pray" tactics! The Wolf Framework helps you pinpoint specific actions that drive real results. 🎯 ⏹ Delivers measurable outcomes: Define clear metrics from the outset, allowing you to track progress and demonstrate the tangible value your brand strategy delivers. 📊 Here's what you can expect with the Wolf Medical Strategy Framework: 👉 Increased brand focus and consistency - Eliminate confusion and ensure your messaging resonates across all touchpoints. 🎯 👉 Improved stakeholder engagement - Build stronger relationships by addressing their specific needs and priorities. 🪢 👉 Measurable ROI - Track progress with clear metrics, showcasing the true impact of your Medical strategy to leadership. 📊 Here some recent feedback from a Strategy Training Workshop I ran with Medical Strategy Leads: “The workshop delivered by Wolf Medical proved extremely valuable in elevating our medical strategy planning process. The framework provided clarity and structure, supporting us in focusing on the gaps we were trying to address and the overall impact of individual tactics. I’d highly recommend the workshop to medical affairs colleagues looking to invest in their strategic planning capabilities” Are you ready to turn brand strategy into action? Let's chat! I offer a free consultation to discuss your specific needs and how the Wolf Medical Framework can help you achieve Medical Affairs Impact. #MedicalAffairs #BrandStrategy #MedicalImpact P.S. Looking for additional resources? Download the free Wolf Medical guide on "Five Steps to a Successful Medical Strategy." Just comment “Yes” below! 👇

15

3 Comments

#News: Halda Therapeutics, a Connecticut-based biotech founded by Yale professor and entrepreneur Craig Crews, announced Monday that it has raised $126 million in a #SeriesB extension to move two candidates into #clinicaltrials for patients with #prostate and #breast #cancer. The #biotech has been developing a new class of #cancertherapies known as #RegulatedInducedProximityTargetingChimeras (RIPTAC). According to Halda, these assets use a “hold and kill” mechanism using two proteins, one cancer-specific and one with an essential function. The candidates are designed to help retract essential cell function and cause the death of the cancer cells while preserving non-cancer tissue. “This financing will enable us to bring to patients our oral, selective and widely applicable cancer cell-killing mechanism that is designed to overcome drug resistance, which is a major shortcoming of many current standard of care cancer treatments,” Kat Kayser-Bricker, Halda chief scientific officer, said in a statement. Read more from BioSpace 👇🏼

4